ArticleBriefings in bioinformatics2025
PCLSurv: a prototypical contrastive learning-based multi-omics data integration model for cancer survival prediction.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TMO-Net+: An Enhanced Tumor Multi-Omics Pre-Trained Network for Multi-Task Learning in Oncology.Genes · 2026Article
- Foundation models in omics research: a comprehensive survey.Briefings in bioinformatics · 2026Review
- PIMO: pathway-based interpretable multiomics interactions for multiomics integration.Bioinformatics (Oxford, England) · 2026Article
- Cancer survival prediction based on soft-label guided contrastive learning and global feature fusion.Bioinformatics (Oxford, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Accurate cancer survival prediction remains a critical challenge in clinical oncology, largely due to the complex and multi-omics nature of cancer data. Existing methods often struggle to capture the comprehensive range of informative features required for precise predictions. Here, we introduce PCLSurv, an innovative deep learning framework designed for cancer survival prediction using multi-omics data. PCLSurv integrates autoencoders to extract omics-specific features and employs sample-level contrastive learning to identify distinct yet complementary characteristics across data views. Then, features are fused via a bilinear fusion module to construct a unified representation. To further enhance the model's capacity to capture high-level semantic relationships, PCLSurv aligns similar samples with shared prototypes while separating unrelated ones via prototypical contrastive learning. As a result, PCLSurv effectively distinguishes patient groups with varying survival outcomes at different semantic similarity levels, providing a robust framework for stratifying patients based on clinical and molecular features. We conduct extensive experiments on 11 cancer datasets. The comparison results confirm the superior performance of PCLSurv over existing alternatives. The source code of PCLSurv is freely available at https://github.com/LiangSDNULab/PCLSurv.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.